Fenticonazole in the treatment of vaginal candidiasis

D. Schneider, E. Caspi, S. Arieli, I. Bukowski, E. Colli

Research output: Contribution to journalArticlepeer-review


The therapeutic activity of a single fenticonazole 600 mg ovule was studied in 72 women (median age 21 years, range 18-62) with mycologically/microbiologically confirmed vaginal candidiasis alone (54 cases) or in association with other infective agents apart from Trichomonas sp (18 cases). Therapeutic activity was assessed by microbiological and clinical criteria 7 days and 4 weeks after the start of treatment. At the first follow-up visit there was a statistically significant reduction in clinical symptom score (erythema, itching, discharge, edema) from 4.56 to 0.56 (p<0.01). This improvement was confirmed by the physician's overall clinical assessment of the efficacy of treatment: 69 women were judged cured or markedly improved on day 7. The disease was evaluated as unchanged or worse in the remaining 3 patients. Mycological/microbiological findings were negative in 55 (76%) cases, 6 cases were positive for Candida (8%), and 11 cases (15%) were negative for Candida but positive for other infective agents. On the basis of symptomatology and mycological/microbiological findings, clinical response was reassessed 4 weeks after treatment: overt disease was present in 1 case, subclinical disease in 3, and 68 were disease free. There was no report of any systemic or local adverse effect. These findings confirm the efficacy and safety of fenticonazole ovules in the treatment of vaginal candidiasis.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalAdvances in Therapy
Issue number6
StatePublished - 1990


Dive into the research topics of 'Fenticonazole in the treatment of vaginal candidiasis'. Together they form a unique fingerprint.

Cite this